Humacyte, Inc. Net Income
Humacyte, Inc. (HUMA) reported Net Income of -$36.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-12
- Humacyte, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$36.80M.
- Humacyte, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$17.62M, a 145.02% decline year-over-year.
- Humacyte, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$24.80M.
- Humacyte, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$17.51M.
- Humacyte, Inc. net income (loss) attributable to parent for fiscal 2023 was -$110.78M.
- Humacyte, Inc. net income (loss) attributable to parent for fiscal 2022 was -$11.96M.
- Humacyte, Inc. net income (loss) attributable to parent for fiscal 2021 was -$26.48M.
- Humacyte, Inc. net income (loss) attributable to parent for fiscal 2020 was -$66.52M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$36.80M 10-Q · filed 2026-08-12 | -$54.42M 10-Q · filed 2026-08-12 | -$79.23M derived: sum of 3 quarters · filed 2026-08-12 | -$96.74M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2026-03-31 | -$17.62M 10-Q · filed 2026-08-12 | -$42.42M derived: sum of 2 quarters · filed 2026-08-12 | -$59.93M derived: sum of 3 quarters · filed 2026-08-12 | -$97.59M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-12-31 | -$24.80M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$42.31M derived: sum of 2 quarters · filed 2026-04-28 | -$79.97M derived: sum of 3 quarters · filed 2026-08-12 | -$40.83M DEF 14A · filed 2026-04-28 | -$40.83M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | -$17.51M 10-Q · filed 2025-11-12 | -$55.17M derived: sum of 2 quarters · filed 2026-08-12 | -$16.03M 10-Q · filed 2025-11-12 | -$36.97M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-06-30 | -$37.66M 10-Q · filed 2026-08-12 | $1.48M 10-Q · filed 2026-08-12 | -$19.46M derived: sum of 3 quarters · filed 2026-08-12 | -$58.66M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-03-31 | $39.14M 10-Q · filed 2026-08-12 | $18.20M derived: sum of 2 quarters · filed 2026-08-12 | -$21.00M derived: sum of 3 quarters · filed 2026-08-12 | -$77.67M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2024-12-31 | -$20.94M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$60.14M derived: sum of 2 quarters · filed 2026-04-28 | -$116.81M derived: sum of 3 quarters · filed 2026-04-28 | -$148.70M DEF 14A · filed 2026-04-28 | -$148.70M 10-K · filed 2025-03-31 | ||
| 2024-09-30 | -$39.20M 10-Q · filed 2025-11-12 | -$95.86M derived: sum of 2 quarters · filed 2025-11-12 | -$127.76M 10-Q · filed 2025-11-12 | -$152.87M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | -$56.66M 10-Q · filed 2025-11-12 | -$88.56M 10-Q · filed 2025-08-11 | -$113.67M derived: sum of 3 quarters · filed 2025-11-12 | -$139.66M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-03-31 | -$31.90M 10-Q · filed 2025-11-12 | -$57.00M derived: sum of 2 quarters · filed 2025-11-12 | -$83.00M derived: sum of 3 quarters · filed 2025-11-12 | -$105.70M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2023-12-31 | -$25.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$51.10M derived: sum of 2 quarters · filed 2025-03-31 | -$73.81M derived: sum of 3 quarters · filed 2025-03-31 | -$110.78M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$26.00M 10-Q · filed 2024-11-08 | -$48.70M derived: sum of 2 quarters · filed 2024-11-08 | -$85.67M 10-Q · filed 2024-11-08 | -$89.39M derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2023-06-30 | -$22.71M 10-Q · filed 2024-11-08 | -$59.67M 10-Q · filed 2024-08-13 | -$63.40M derived: sum of 3 quarters · filed 2024-11-08 | -$88.68M derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2023-03-31 | -$36.97M 10-Q · filed 2024-11-08 | -$40.69M derived: sum of 2 quarters · filed 2024-11-08 | -$65.97M derived: sum of 3 quarters · filed 2024-11-08 | -$29.10M derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2022-12-31 | -$3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$29.00M derived: sum of 2 quarters · filed 2024-03-28 | $7.87M derived: sum of 3 quarters · filed 2024-03-28 | -$11.96M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | -$25.28M 10-Q · filed 2023-11-09 | $11.59M derived: sum of 2 quarters · filed 2023-11-09 | -$8.24M 10-Q · filed 2023-11-09 | $34.34M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $36.87M 10-Q · filed 2023-11-09 | $17.04M 10-Q · filed 2023-08-14 | $59.62M derived: sum of 3 quarters · filed 2023-11-09 | $28.06M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-03-31 | -$19.83M 10-Q · filed 2023-11-09 | $22.75M derived: sum of 2 quarters · filed 2023-11-09 | -$8.81M derived: sum of 3 quarters · filed 2023-11-09 | -$26.01M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2021-12-31 | $42.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $11.02M derived: sum of 2 quarters · filed 2023-03-24 | -$6.18M derived: sum of 3 quarters · filed 2023-03-24 | -$26.48M 10-K · filed 2023-03-24 | |||
| 2021-09-30 | -$31.56M 10-Q · filed 2022-11-10 | -$48.76M derived: sum of 2 quarters · filed 2022-11-10 | -$69.06M 10-Q · filed 2022-11-10 | -$49.88M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | -$17.20M 10-Q · filed 2022-11-10 | $286.22K 10-Q · filed 2021-08-16 | -$37.50M 10-Q · filed 2022-08-12 | -$9.15M 10-Q · filed 2021-08-16 | -$18.32M derived: sum of 3 quarters · filed 2022-11-10 | -$36.08M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-03-31 | -$20.30M 10-Q · filed 2022-11-10 | -$9.44M 10-Q · filed 2021-05-17 | -$1.12M derived: sum of 2 quarters · filed 2022-11-10 | -$18.88M derived: sum of 3 quarters · filed 2022-11-10 | -$33.76M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2020-12-31 | $19.18M derived: 10-K/A 6 month − 10-Q 3 month · filed 2021-05-14 | $1.42M 10-K/A · filed 2021-05-14 | -$233.33K 10-K · filed 2021-02-16 | -$13.46M derived: sum of 3 quarters · filed 2021-11-15 | -$66.52M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | -$17.76M 10-Q · filed 2021-11-15 | -$40.95K 10-Q · filed 2020-11-13 | -$32.64M derived: sum of 2 quarters · filed 2021-11-15 | -$50.31M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$14.88M 10-Q · filed 2021-11-15 | -$32.55M derived: sum of 2 quarters · filed 2021-11-15 | |||||
| 2020-03-31 | -$17.67M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |